Sugarnon (evogliptin) / Dong-A  >>  Phase 1
Welcome,         Profile    Billing    Logout  

9 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sugarnon (evogliptin) / Dong-A
NCT00961025: A Study to Characterize the Pharmacokinetics/Pharmacodynamics and Effect of Food of DA-1229 in Healthy Male Subjects

Unknown status
1
110
RoW
DA-1229, Placebo
Dong-A Pharmaceutical Co., Ltd.
Diabetes Mellitis Type 2
02/10
03/10
NCT01941199: Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of DA-1229 and Metformin After Oral Administration in Healthy Male Subjects

Completed
1
36
RoW
DA-1229, metformin, DA-1229 + metformin
Dong-A Pharmaceutical Co., Ltd.
Type 2 Diabetes Mellitus
11/13
 
NCT02267902: Microtracer Study to Establish Absolute Bioavailability and the Absorption, Metabolism, Excretion of DA-1229

Unknown status
1
12
Europe
DA-1229
Dong-A ST Co., Ltd.
Healthy
01/15
01/15
NCT02214693: PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients

Completed
1
30
RoW
DA-1229, Evogliptin
Dong-A ST Co., Ltd.
Renal Impairment
03/15
 
NCT02753803: Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5 mg and Pioglitazone 30 mg

Completed
1
36
RoW
Evogliptin, Pioglitazone, Evogliptin+Pioglitazone, Suganon, Actos, Pioglitazone, Evogliptin, Evogliptin+Pioglitazone, Evogliptin, Evogliptin+Pioglitazone, Pioglitazone, Pioglitazone, Evogliptin+Pioglitazone, Evogliptin, Evogliptin+Pioglitazone, Evogliptin, Pioglitazone, Evogliptin+Pioglitazone, Pioglitazone, Evogliptin
Dong-A ST Co., Ltd.
Type 2 Diabetes
10/16
03/17
NCT02954822: Pharmacokinetic/Pharmacodynamic Drug-drug Interaction of Evogliptin 5mg and Glimepiride 4mg

Completed
1
36
RoW
Evogliptin→Evogliptin+Glimepiride→Glimepiride, Suganon, Amaryl, Glimepiride→Evogliptin→Evogliptin+Glimepiride
Dong-A ST Co., Ltd.
Type2 Diabetes
01/17
08/17
NCT02754219: Pharmacokinetics and Safety of Evogliptin in Subjects With Hepatic Dysfunction

Completed
1
24
RoW
Evogliptin, DA-1229
Dong-A ST Co., Ltd.
Liver Dysfunction
01/18
01/18
NCT03766724: Pharmacokinetic and Pharmacodynamic Drug-Drug Interaction of Evogliptin and Empagliflozin or Dapagliflozin in Healthy Male Adults

Completed
1
42
RoW
Evogliptin→Evogliptin+Empagliflozin→Empagliflozin, Suganon, Jardiance, Empagliflozin→Evogliptin→Evogliptin+Empagliflozin, Evogliptin→Evogliptin+Dapagliflozin→Dapagliflozin, Forxiga, Dapagliflozin→Evogliptin→Evogliptin+Dapagliflozin
Dong-A ST Co., Ltd.
Type2 Diabetes
01/19
01/19
NCT04195919: The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients

Completed
1
17
RoW
Evogliptin 5mg, Suganon
Dong-A ST Co., Ltd.
Hemodialysis Patients
05/21
05/21

Download Options